J2HBiotech

About J2HBiotech

J2H Biotech, founded in 2014 and headquartered in Suwon-si, South Korea, is a biopharmaceutical company focused on developing synthetic drugs for rare, intractable, and infectious diseases. The company aims to provide new therapeutic options for conditions with high unmet medical needs by developing innovative treatments that improve patients' quality of life. A key area of focus is enhancing the oral absorption rate of drugs to offer differentiated therapeutic alternatives.

The company balances innovative drug development with a stable revenue business through its Active Pharmaceutical Ingredient (API) division and Contract Development and Manufacturing Organization (CDMO) services. This dual-pillar strategy allows for reinvestment into its R&D pipeline. The API division operates two GMP-certified facilities in Ansan and Asan, producing high-value APIs and offering end-to-end support from R&D to commercial-scale manufacturing. J2H Biotech's pipeline includes candidates for Metabolic Dysfunction-Associated Steatohepatitis (MASH), multiple sclerosis, and non-small cell lung cancer. Its lead candidate, J2H-1702 for MASH, has completed Phase 1 trials and entered Phase 2 trials in 2022.

Since its inception, J2H Biotech has achieved significant milestones, including being certified as a Company-Affiliated Research Institute in 2015 and recognized as a Preliminary Unicorn Company by the Ministry of SMEs and Startups. The company has successfully licensed out two new drug candidates and has raised approximately $51.9 million in funding from investors including Company K Partners, IMM Investment, and Aju IB Investment.